Citations

Clear

3641 citation(s) found for "South, AP".

CARE: A Multi-Agent Framework for Real-Time Adaptive Vocal Interaction in Dementia Care
Yaddanapalli, Bharat Sowrya , Zhang, Jiaxuan , Williams, Toby, Markanti, Rithika , Fu, Anthony, Fonzo, Ian, Villalobos, Sebastian Boscan, Wu, Dezhi, Wang, Xiaofeng, Tao, Cui

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1191-1193

10.1109/ichi69079.2026.00152 Get It

Prescription Trends for Bipolar Disorder With and Without Comorbid Substance Use and Anxiety Disorders: A Global Bipolar Cohort Collaborative Study
Yocum, Anastasia K. , Aouizerate, Bruno, Aubin, V. , Bellivier, Frank , Belzeaux, Raoul , Berk, Michael , Biernacka, Joanna M. , Budde, Monika , Burdick, Katherine E. , Coombes, Brandon J., Diaz‐Byrd, Claudia , Dubertret, Caroline, Fico, Giovanna, Godin, Ophélia , Gordon‐Smith, Katherine, Januel, Dominique, Lefrère, Antoine , Llorca, Pierre‐Michel, Mwangi, Benson, Olie, Emilie, Overs, Bronwyn J. , Petite, Joanne, Polosan, Mircea , Rey, Romain, Roberts, Gloria, Schwan, Raymund, Serretti, Alessandro , Soares, Jair C., Stross, Tatjana , Walter, Michel, Williams, Lana J., Wu, Mon‐Ju, Young, Allan H. , Zunta‐Soares, Giovana B., Frye, Mark A. , McInnis, Melvin G., Roberts, Gloria , Alda, Martin , Bellivier, F , Belzeaux, Raoul , Berk, Michael , Biernacka, Joanna , Budde, Monika , Burdick, K E , Chang, Yun-Hsuan , Courtet, Philippe , Dalkner, Nina , Etain, B , Fullerton, Janice M , Godin, Ophelia , Haffen, Emmanuel , Keramatian, Kamyar , Leboyer, Marion , Majd, Marzieh , Mitchell, Philip B , Polosan, Mircea , Roux, Paul , Samalin, Ludovic , Serretti, Alessandro , Sperry, Sarah , Strawbridge, Rebecca , Stross, Tatjana , Vieta, E , Williams, Lana J , Yatham, Lakshmi N , Young, Allan H , Yrondi, Antoine , Frye, Mark , Singh, Balwinder , Alda, Martin , Aouizerate, Bruno , Coombes, Brandon J. , Dubertret, Caroline , Étain, Bruno , Fico, Giovanna , Fullerton, Janice M. , Gordon‐Smith, Katherine , Januel, Dominique , Keramatian, Kamyar , Leboyer, Marion , Llorca, Pierre‐Michel , Mwangi, Benson , Olié, Émilie , Rey, Romain , Samalin, Ludovic , Schwan, Raymund , Soares, Jair C. , Sperry, Sarah H. , Strawbridge, Rebecca , Vieta, Eduard , Walter, Michel , Wu, Mon‐Ju , Yatham, Lakshmi N. , Zunta‐Soares, Giovana B. , McInnis, Melvin G. , Singh, Balwinder

Mayo Clinic

Bipolar Disorders | August 11, 2026 | Volume: 28 | Issue: 6 | Pages: No page available

10.1111/bdi.70167 | PMID 42578538 Get It

ABSTRACT Objectives To investigate pharmacological treatment patterns in individuals with bipolar disorder (BD) with and without comorbid substance use disorder (SUD) and anxiety disorder (AX), we leveraged the Global Bipolar Cohort to analyze cross‐regional practices across North America, Europe, and the Pacific. Methods Fourteen cohorts contributed aggregate data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities. Proportional meta‐analyses using generalized linear mixed models were conducted to examine prescription trends and identify clinical differences. Results The sample ( N = 11,521) was 60% female and 84% Caucasian. Participants were categorized into four mutually exclusive groups based on comorbidity status: those with comorbid AX only, comorbid SUD only, both AX and SUD, or neither. The AX+SUD subgroup showed higher rates of attention‐deficit/hyperactivity disorder (ADHD), post‐traumatic stress disorder (PTSD), rapid cycling, obesity, and unemployment, reflecting a more severe clinical profile. Regional variations were notable: North American cohorts reported higher prevalence of AX and SUD than European and Pacific cohorts. Antidepressants use for AX were more common in Europe and the Pacific, while North American prescribing patterns were more variable. Benzodiazepine use was high among individuals with SUD across all regions. Lithium and first‐generation antipsychotic prescriptions varied, with higher rates observed in Europe. Conclusions Findings underscore the heterogeneity of BD and the influence of comorbid AX and SUD on illness burden and treatment. Regional prescribing variations underscore the need for context‐specific guidelines. Gaps in data on medication‐assisted treatment for SUD point to areas for future research. These insights can support more individualized and effective care for complex BD presentations.
A shared injury–homeostasis gradient in the human CSF proteome across neurological disease
Mansouri, Alireza , Mikolajewicz, Nicholas , Riviere-Cazaux, Cécile , Tuohy, Kyle , Kumar, Rahul , Miller, Alexandra, Ahluwalia, Manmeet S. , Bettegowda, Chetan , Burns, Terry, Mansouri, Alireza , Ahluwalia, Manmeet S , Kumar, Rahul , Bettegowda, Chetan , Tuohy, Kyle , Ranganathan, Sruthi , Boutros, Paul C. , Kislinger, Thomas , Mikolajewicz, Nicholas , Boutros, Paul C , Kislinger, Thomas

Mayo Clinic

No container title available | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10480838/v1 | PMID 42845524 Get It

Abstract Cerebrospinal fluid (CSF) is the biofluid most proximal to the central nervous system (CNS), yet its proteomic organization across neurological disease remains unresolved. We assembled a meta-atlas of 35 CSF proteomic datasets (2016–2026) comprising 10,560 quality-controlled samples spanning neurodegenerative, neuroinflammatory, neuro-oncological, infectious and structural-injury contexts. Meta-analysis of cross-cohort detection defined a 747-protein core mass-spectrometry-accessible CSF proteome that generalizes to held-out cohorts. We derived thirteen consensus meta-programs that transfer across independent cohorts and span the major neural, barrier, immune and plasma compartments. Unexpectedly, these programs are dominated by a single axis of variation opposing complement- and plasma-associated inflammation against neuronal-synaptic homeostasis. This injury–homeostasis axis is diagnosis-spanning and tracks clinical severity and disease activity across diverse neurological conditions. We show that a two-protein C5–NRCAM model can approximate the injury–homeostasis axis, bridging deep proteomic profiling toward bedside assessment.
Incidence of Acute Cystoid Macular Edema After Penetrating Keratoplasty and Endothelial Keratoplasty
Qozat, Ibrahim , Abubaker, Yazan , Vasu, Pranav, Wagner, Isabella, Lentz, Conner, Ahuja, Abhimanyu, Miller, Darby, Stewart, Michael, Dorairaj, Syril, Qozat, Ibrahim , Vasu, Pranav , Wagner, Isabella V. , Dorairaj, Emily , Miller, Darby D. , Stewart, Michael W., Dorairaj, Syril

Mayo Clinic

Klinische Monatsblätter für Augenheilkunde | August 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2932-7648 | PMID 42570678 Get It

Abstract Introduction Cystoid macular edema (CME) is a recognized complication associated with penetrating keratoplasty (PK) and Endothelial Keratoplasty (EK). The purpose of this study was to determine the incidence of acute CME within the first 6 months after PK, Descemet stripping automated EK, or Descemet’s membrane EK. Methods A retrospective cohort analysis of the TriNetX United States collaborative database was conducted. Patients with a diagnosis of Fuchs dystrophy or keratoconus who underwent PK or EK between January 1, 2004 and August 30, 2024 were included. Those with a history of uveitis, retinal vascular occlusion, diabetic macular edema, or prior vitrectomy were excluded. Outcomes and diagnoses were defined using current procedural terminology and International Classification of Diseases, Tenth edition (ICD-10) codes. Cohorts were stratified based on a history of prior PK or EK with >6 months follow-up. Propensity score matching was performed on both cohorts to control for age at index, sex, race, ethnicity, and the diagnosis of Fuchs dystrophy and keratoconus. The incidence of acute CME during a 6-month postoperative follow-up period was assessed. Odds ratios were calculated between cohorts. Results A total of 2516 eyes were included in the study (PK: 1258; EK: 1258). At six months postoperatively, the incidence of acute CME in the EK cohort (46 of 1258) was significantly higher than in the PK cohort (20 of 1258) (P = 0.0012) (OR 0.426, 95% confidence interval 0.25–0.72). Conclusions Our findings suggest that the incidence of acute CME is higher in patients undergoing EK compared to PK.
Spatial multi-omics and single-cell transcriptomics uncover senescence-associated cellular programs during colon adenoma to cancer progression
Yu, Ming , Xie, Yumo , Allen, Lena, Carter, Kelly , Donato, Elizabeth , Cheng, Lingxin , Kendziorski, Christina , Hall, Lance T. , Marzo, Angelo M. De , Hicks, Jessica, Reddi, Deepti , Sun, Wei, Matkowskyj, Kristina A , De Marzo, Angelo M , Newell, Evan W , Grady, William M , Carter, Kelly , Reddi, Deepti , Sun, Wei, Grady, William M.

Mayo Clinic

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.06.743310 | PMID 42620287 Get It

Abstract Colorectal cancer develops through a normal-adenoma-carcinoma sequence, yet only 5-10% of adenomas progress to malignancy, and the cellular programs governing that sequence remain poorly defined. Here we generate a spatial multi-omics atlas of human colon adenomas, combining Visium CytAssist and protein co-detection across 24 nonadvanced and advanced tubular adenomas with single-cell resolution Xenium Prime 5K profiling of 101 patient-matched normal, adenoma, and carcinoma cores from 16 patients. Integrating whole-transcriptome and 31-plex protein data identifies nine spatial clusters and two dysplastic epithelial populations that co-express stemness, proliferation, and senescence programs. These programs occupy a shared, spatially confined epithelial niche that expands from adenoma to carcinoma. Spatial analysis revealed GDF15, a senescence-associated secretory factor, mediated the coupling between senescence and stemness in advanced adenomas, and that GDF15-high epithelium locally excludes CD8+ T cells in adenoma and, more broadly, in carcinoma. These findings position senescence as a spatially instructive rather than merely tumor-suppressive program during colorectal carcinogenesis and suggest GDF15 might be a potential candidate target for cancer prevention and interception in the colon.
Glomerular-Targeted Delivery of Low-Dose Prednisolone Attenuates Established Lupus Nephritis in MRL/lpr Mice
Williams, Kristof , Agyekum, Georgina , Patne, Akshata, Markoutsa, Eleni, Chellappan, David Raj, Hall, Nathan, Tian, Zhi , Soto, Nohely Hernandez, Cuadrao, Sebastian, Lozonschi, Isabella, Fu, Liying, Haight, Lilliana, Sharma, Rahul, Mohapatra, Subhra, Wang, Lei, Liu, Ruisheng, Fu, Liying, Sharma, Rahul, Wang, Lei , Mohapatra, Shyam S. , Liu, Ruisheng

Mayo Clinic

No container title available | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.01.742194 Get It

Abstract Background Lupus nephritis remains a major cause of chronic kidney disease and kidney failure in systemic lupus erythematosus. Glucocorticoids are central to treatment but are limited by systemic toxicity. We evaluated whether a previously characterized collagen IV α3-targeted liposomal nanoparticle formulation carrying low-dose prednisolone could attenuate established lupus nephritis in MRL/lpr mice. Methods Female MRL/lpr mice with disease present at treatment initiation and C57BL/6J control mice received saline or collagen IV α3-targeted prednisolone-loaded nanoparticles (Col4-α3-Pred-NPs). Renal outcomes were assessed by longitudinal proteinuria, glomerular filtration rate (GFR), survival, kidney histopathology, renal IgG and C3d deposition, dUTP/TUNEL-associated injury staining, and renal cytokine/chemokine profiling. Body weight, food and water intake, and blood glucose were monitored as measures of general condition and preliminary tolerability. Results Col4-α3-Pred-NPs improved survival in MRL/lpr mice, reduced cumulative proteinuria burden, and attenuated terminal GFR decline compared with saline-treated MRL/lpr controls. Treatment reduced glomerular and tubulointerstitial injury, lowered composite EGTI histopathology scores, decreased terminal kidney enlargement, reduced glomerular IgG deposition and renal dUTP-positive injury signals, and reduced renal signals for IL-28A/B, IL-7, PD-ECGF, IL-11, CCL6/C10, and IL-15. C3d deposition was not significantly altered. Nanoparticle treatment was not associated with sustained treatment-related increases in blood glucose or body-weight loss during the measured study period. Conclusions Collagen IV α3-targeted liposomal delivery of low-dose prednisolone attenuated established lupus nephritis in MRL/lpr mice and improved renal structural, functional, inflammatory, and survival outcomes. These findings support further evaluation of glomerulus-targeted nanotherapy as a potential strategy to improve the precision and therapeutic index of glucocorticoid treatment in lupus nephritis.
Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel
Tibben, Bailey M. , Maillard, Maud , Pratt, Victoria M. , Moyer, Ann M. , Figueroa, Debbie M. , Gaedigk, Andrea , Stocco, Gabriele , Schwab, Matthias , Caudle, Kelly E. , Whirl-Carrillo, Michelle , Gaedigk, Andrea , Stocco, Gabriele , Schwab, Matthias , Caudle, Kelly E , Yang, Jun J.J. , Maillard, Maud , Figueroa, Debbie M , Whirl‐Carrillo, Michelle

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/cpt.70433 | PMID 42560154 Get It

The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles. These genes are critical for the metabolism of thiopurines, which are widely used in the treatment of cancer and autoimmune disorders. Standardized allele function assignment is essential for predicting metabolizer phenotypes and pharmacogenetics‐guided thiopurine dosing. The work presented here includes the first designation of decreased function alleles for both TPMT and NUDT15 , reflecting new clinical data that demonstrate partial loss of enzymatic activity and reduced dose tolerance. The panel also reclassified several alleles previously assigned uncertain or unknown function. The functional assignments were informed by a standardized framework incorporating clinical data, such as thiopurine tolerance and toxicity, as well as in vitro protein activity, ex vivo enzymatic measurements, and in silico variant effect prediction tools. These updates enhance the precision of genotype‐to‐phenotype mapping and support more personalized thiopurine therapy across diverse patient populations.
Beyond Doppler: Scalable AI Detection of LVOT Obstruction in HCM
Crystal, Owen , Farina, Juan M. , Scalia, Isabel G. , Ayoub, Chadi , Chollet, Laurève , Park, Hyung‐Bok , Kim, Kyung An , Arsanjani, Reza , Lester, Steven J., Crystal, Owen R , Villa Etchegoyen, Cecilia , Chollet, Laurève , Park, Hyung Bok , Kim, Kyung An , Arsanjani, Reza , Banerjee, Imon , Farina, Juan M , Scalia, Isabel G , Etchegoyen, Cecilia Villa , Lester, Steven J., Banerjee, Imon

Mayo Clinic

Circulation: Cardiovascular Imaging | August 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circimaging.126.019956 | PMID 42558066 Get It

BACKGROUND: Accurate assessment of left ventricular outflow tract (LVOT) gradients is critical for hypertrophic cardiomyopathy management, yet Doppler-based measurements are technically demanding and require expertise. The objective of this work was to develop a multi-view deep learning model capable of classifying LVOT obstruction (>20 mm Hg) using routine 2-dimensional echocardiographic windows without reliance on Doppler imaging. METHODS: We trained and externally validated a cross-attention-based video-to-video fusion framework that integrated EchoPrime-derived video representations from 3 standard transthoracic echocardiographic views to classify LVOT gradients. RESULTS: Training was performed on a derivation cohort (N=1833) from a tertiary care system in the United States, with model performance evaluated on an internally held-out test set (N=275) and a Korean external validation cohort (N=46). Single-view baselines showed limited discrimination (external area under the receiver operating curves, 0.47–0.70). Conversely, the domain-specific foundational model (EchoPrime) achieved superior single-view performance (area under the receiver operating curves, 0.75–0.80 internal; 0.79–0.83 external), highlighting the importance of echo-specific pretraining and temporal modeling. The proposed multi-view fusion further enhanced predictive performance, with the late fusion model reaching an area under the receiver operating curve of 0.84 on the external cohort with significant population-shift. CONCLUSIONS: These results suggest LVOT physiology is encoded in routine 2-dimensional imaging and can be leveraged for clinically relevant gradient classification without Doppler input. The proposed artificial intelligence-guided strategy demonstrates substantial cost savings compared with the screen-all approach. By integrating complementary spatial-temporal information across multiple views, our approach generalizes robustly across populations and may enable real-time decision support, extend LVOT assessment to portable or resource-limited settings, and complement Doppler-based evaluation for longitudinal hypertrophic cardiomyopathy management.
Glomerulus-targeted nanotherapy via collagen IV-α3 binding enhances renal immunoregulation in lupus nephritis
Wang, Lei , Markoutsa, Eleni, Venkatadri, Rajkumar , Sharma, Rahul, Esquivel, Carlos, Patne, Akshata, Wei, Jin, Zhang, Jie, Williams, Kristof , Lawless, William, Muskan, Amtul, Fu, Liying, Mayilsamy, Karthick, Mohapatra, Subhra, Mohapatra, Shyam, Liu, Ruisheng, Sharma, Rahul, Esquivel, Carlos O. , Mayilsamy, Karthick , Mohapatra, Shyam, Liu, Ruisheng

Mayo Clinic

Clinical Science | August 5, 2026 | Volume: 140 | Issue: 9 | Pages: 1895-1913

10.1042/cs20261409 | PMID 42554713 Get It

Abstract Lupus nephritis (LN) requires long-term immunosuppressive therapy, which is often associated with severe systemic side effects. Therefore, new therapeutic strategies that maintain high efficacy while minimizing adverse effects are essential. Although nanomedicine has advanced systemic and kidney-targeted drug delivery, a reliable method for glomerulus-specific delivery is lacking. Collagen IV (Col4)-alpha 3, located in the glomerular basement membrane at the blood–tissue interface through fenestrated capillary endothelium, represents an ideal target for glomeruli delivery. Herein, we developed a novel liposomal nanoparticle conjugated with a Col4-alpha 3-binding peptide (Col4-α3-NPs) for selective glomerular targeting. Prednisolone-loaded Col4-α3-NPs were administered to lupus-prone mice twice weekly for 8 weeks. Kidney injury and function were evaluated biweekly, and renal immune cell populations were analyzed by flow cytometry at study completion. The results show that rhodamine-labeled NPs predominantly accumulate in kidney glomeruli 48 h after intravenous injection. The Col4-NP system demonstrated stable and prolonged release of the encapsulated drug for over 48 h. Lupus-prone mice treated with prednisolone-loaded Col4-NPs showed significantly improved renal function and histology, including a 30% increase in glomerular filtration rate, a 56% reduction in proteinuria, and decreased IgG deposition and fibrosis. Notably, treatment also enhanced renal regulatory T cell populations. These findings suggest that glomerulus-targeted Col4-α3-NPs hold significant translational promise. This platform may offer an effective, site-specific treatment for LN while minimizing systemic side effects and could be adapted for other glomerular diseases requiring targeted therapy.